As global clinical development becomes more complex, China continues to play a critical role in scientific innovation, patient diversity, and biotech growth. Sponsors running global and multi regional clinical trials increasingly need partners that can operate with local precision while maintaining global consistency. To support this demand, Precision has expanded its footprint in Greater China. In this context, Greater China includes Mainland China, Hong Kong, and Taiwan, each with distinct regulatory and operational requirements.
This expansion reflects a long-term commitment to building on-the-ground capability, regional insight, and globally aligned execution that helps sponsors move faster and with greater confidence in China and beyond. Precision for Medicine partners with a total of six Precision Site Network sites across Greater China, including one in Taiwan.
Over the past decade, China’s life sciences ecosystem has evolved rapidly. The country is now home to a growing biotech sector, an increasingly sophisticated regulatory environment, and research institutions that play a central role in global development programs.
At the same time, sponsors often face friction when translating global trial strategies into effective local execution. Differences in regulatory interpretation, site operations, investigator engagement, and patient pathways can create risk if not managed closely. Success in China requires local presence, cultural understanding, and the ability to align regional execution with global quality standards.
By establishing offices in Beijing, Shanghai, Hong Kong and Taiwan, Precision is positioned to bridge this gap, enabling sponsors to navigate complexity without compromising speed or compliance.
Beijing sits at the intersection of scientific leadership and regulatory decision-making. With proximity to academic institutions, medical centers, and regulatory stakeholders, our Beijing office supports early scientific engagement, regulatory dialogue, and strategic planning that helps programs move forward with clarity.
Shanghai is China’s primary hub for biotech innovation and clinical trial activity. Our Shanghai team works closely with sponsors, sites, and partners to support operational delivery, cross-functional coordination, and day-to-day trial execution across phases and therapeutic areas.
Hong Kong serves as a critical gateway between China and global research networks. Its international environment and accessibility make it an ideal base for regional trial management, cross-border coordination, and integration with global development teams.
Taiwan requires a distinct regulatory and operational approach, supported by local expertise and in-country staff. Precision’s Taiwan presence enables sponsors to address Taiwan’s specific regulatory requirements while maintaining alignment with global development strategies. Local teams support site engagement, regulatory coordination, and execution tailored to Taiwan’s separate regulatory framework.
With teams positioned across four strategic hubs, Precision enables sponsors to benefit from:
Closer site and investigator engagement that supports faster feasibility, startup, and issue resolution
More responsive regional operations grounded in local knowledge and decision-making
Strong alignment with global quality standards across regions
Support for multi regional clinical trials that require local execution with centralized coordination
A stronger foundation for China-based innovators expanding into international markets
|
Zhenfei, General Manager, Precision China “Proximity matters. Being close to sites, investigators, and decision-makers allows us to move with greater speed and accountability while maintaining global quality expectations.” |
JingPing, APAC Leadership “China’s role in global development continues to grow. Aligning local execution with regional and global standards gives sponsors a clearer, more predictable path from startup through enrollment.” |
|
James, APAC Leadership “This structure improves coordination and reduces operational risk across multi-regional programs. It is a practical way to protect timelines while maintaining consistency.” |
Sunny, China Medical Manager “Medical oversight is most effective when it is informed by real-time investigator interaction. Local presence allows earlier insight into emerging risks and faster, more pragmatic responses.” |
|
Calvin, Head of Regulatory Affairs, China “Regulatory strategy depends on coordination. With teams in Beijing and Hong Kong, we can engage early, respond quickly, and keep submissions moving without unnecessary delay.” |
Helen, Executive Director, Clinical Operations “Effective clinical execution depends on being close to where decisions are made and studies are run. With teams across Greater China, sponsors gain operational visibility, faster escalation, and tighter coordination across regions.” |
Precision’s model integrates local expertise with a global network of clinical, medical, regulatory, and operational specialists. This approach supports scientific rigor, transparent communication, and consistent execution across regions, helping sponsors manage complexity without losing momentum.
An expanded presence in Beijing, Shanghai, Hong Kong and Taiwan strengthens Precision’s ability to support sponsors operating in one of the world’s most important clinical research environments. As we continue to invest in local talent and partnerships, sponsors gain a trusted partner equipped to navigate regulatory complexity, execute efficiently, and advance innovation with confidence.